-
公开(公告)号:US09994556B2
公开(公告)日:2018-06-12
申请号:US15318351
申请日:2015-06-12
Applicant: THE UNIVERSITY OF KANSAS
Inventor: Jinbo Zhao , Huiping Zhao , Brian S. J. Blagg
IPC: C07D405/14 , C07D401/12
CPC classification number: C07D405/14 , C07D401/12
Abstract: Provided herein are compounds of the formulas: which are 90-kDa heat shock protein inhibitors. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including cancer, e.g., cancers of the breast, the prostate, and the head & neck.
-
82.
公开(公告)号:US20180158663A1
公开(公告)日:2018-06-07
申请号:US15832016
申请日:2017-12-05
Applicant: The University of Kansas
Inventor: Craig E. Lunte , Ryan Tyler Johnson , Nhan To , Susan M. Lunte , Damon Osbourn
IPC: H01J49/16 , G01N30/72 , H01J49/04 , G01N27/447
CPC classification number: H01J49/167 , G01N27/44713 , G01N27/4473 , G01N30/7233 , H01J49/0431
Abstract: Provided herein are capillaries for use in an electrophoretic separations. The capillaries can comprise an elongated tubular wall defining a path for fluid flow from an inlet to a tapered outlet; and a decoupler junction positioned within the elongated tubular wall upstream of the tapered outlet. The decoupler junction can comprise a plurality of microchannels penetrating through the elongated tubular wall and an ion-permeable polymer coating the plurality of microchannels. Also provided are sheathless interfaces for coupling capillary electrophoresis (CE) with mass spectrometry that employ these capillaries.
-
公开(公告)号:US09968553B1
公开(公告)日:2018-05-15
申请号:US15850732
申请日:2017-12-21
Applicant: Silvergate Pharmaceuticals, Inc. , University of Kansas
Inventor: Lian G. Rajewski , Roger A. Rajewski , John L. Haslam , Kathleen Heppert , Michael C. Beckloff , Frank Segrave , Robert Mauro , Peter Colabuono
CPC classification number: A61K9/0095 , A43B11/00 , A61K9/0053 , A61K9/14 , A61K9/143 , A61K9/145 , A61K31/401 , A61K38/05 , A61K45/06 , A61K47/02 , A61K47/26
Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
-
公开(公告)号:US20180116954A1
公开(公告)日:2018-05-03
申请号:US15850732
申请日:2017-12-21
Applicant: Silvergate Pharmaceuticals, Inc. , University of Kansas
Inventor: Lian G. RAJEWSKI , Roger A. RAJEWSKI , John L. HASLAM , Kathleen HEPPERT , Michael C. BECKLOFF , Frank SEGRAVE , Robert MAURO , Peter COLABUONO
CPC classification number: A61K9/0095 , A43B11/00 , A61K9/0053 , A61K9/14 , A61K9/143 , A61K9/145 , A61K31/401 , A61K38/05 , A61K45/06 , A61K47/02 , A61K47/26
Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
-
公开(公告)号:US20180114997A1
公开(公告)日:2018-04-26
申请号:US15815804
申请日:2017-11-17
Applicant: UNIVERSITY OF KANSAS
Inventor: TRUNG VAN NGUYEN , XUHAI WANG
IPC: H01M8/1004
CPC classification number: H01M8/04201 , H01M8/0234 , H01M8/0245 , H01M8/1004 , H01M2008/1095 , H01M2300/0082 , Y02P70/56
Abstract: A gas diffusion layer having a first major surface and a second major surface which is positioned opposite to said first major surface and an interior between said first and second major surfaces is formed. The gas diffusion layer comprises a porous carbon substrate which is directly fluorinated in the interior and is substantially free of fluorination on at least one of the first major surfaces or the second major surfaces, and preferably both surfaces. The gas diffusion layer may be formed using protective sandwich process during direct fluorination or by physically or chemically removing the C—F atomic layer at the major surfaces, for example by physical plasma etching or chemical reactive ion etching.
-
公开(公告)号:US09911539B2
公开(公告)日:2018-03-06
申请号:US14654884
申请日:2013-12-20
Applicant: University of Kansas
Inventor: Shenqiang Ren , Maogang Gong
CPC classification number: H01G9/2013 , H01G9/20
Abstract: Provided are FeS2 based photovoltaic battery devices comprising a transparent substrate, an active layer disposed over the transparent substrate, the active layer comprising a porous film of FeS2 nanocrystals and a halide ionic liquid infiltrating the porous film, and an electrode disposed over the active layer. The device may be configured such that under exposure to light, photons incident on the active layer are absorbed by the FeS2 nanocrystals, generating a current and a voltage, whereby a separation of charge within the active layer is created, which is discharged in the absence of the light.
-
公开(公告)号:US20170314142A1
公开(公告)日:2017-11-02
申请号:US15581387
申请日:2017-04-28
Applicant: University of Kansas
Inventor: Kevin C. Leonard , Joseph M. Barforoush , Tess E. Seuferling , Kelly R. Song
IPC: C25B1/00
CPC classification number: C25B1/003
Abstract: A method for making a metal oxyhydroxide electrocatalytic material comprises titrating a precursor solution with a (bi)carbonate salt, the precursor solution comprising a first metal salt and a solvent, wherein the titration induces reactions between the (bi)carbonate salt and the first metal salt to provide first metal carbonate species in the titrated precursor solution; and exposing the titrated precursor solution to microwave radiation to decompose the first metal carbonate species to form the metal oxyhydroxide electrocatalytic material and carbon dioxide. Mixed metal oxyhydroxide electrocatalytic materials such as nickel-iron oxyhydroxide may be formed. Also provided are the materials themselves, electrocatalytic systems comprising the materials, and methods of using the materials and systems.
-
公开(公告)号:US20170313692A1
公开(公告)日:2017-11-02
申请号:US15498725
申请日:2017-04-27
Applicant: University of Kansas
Inventor: Thomas E. Prisinzano , Andrew P. Riley , Chad E. Groer
IPC: C07D417/14 , C07D405/14 , C07D407/14 , G01N33/50 , C07D401/14 , C07D411/14 , C07D413/14 , C07D407/04
CPC classification number: C07D417/14 , C07D401/14 , C07D405/14 , C07D407/04 , C07D407/14 , C07D411/14 , C07D413/14 , G01N33/5041 , G01N33/9486 , G01N2500/10
Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
-
公开(公告)号:US20170260141A1
公开(公告)日:2017-09-14
申请号:US15529290
申请日:2015-11-25
Applicant: University of Kansas
Inventor: Jeffrey Aube , Kevin Frankowski , Thomas Prisinzano , Laura Bohn
IPC: C07D217/08 , C07D223/16 , C07D209/44
CPC classification number: C07D217/08 , C07D209/44 , C07D223/16
Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.
-
公开(公告)号:US20170218022A1
公开(公告)日:2017-08-03
申请号:US15480120
申请日:2017-04-05
Applicant: The University of Kansas
Inventor: Blake R. Peterson
CPC classification number: C07K7/08 , A61K47/554 , A61K47/65 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6889 , C07K16/2887 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2319/06 , C07K2319/74
Abstract: A peptide can have a sequence of one of SEQ ID NOs: 78-91. A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion having a peptide sequence of one of SEQ NOs: 78-97. A cell-targeting compound can include a conformationally-constrained kinked peptide having a peptide sequence of one of SEQ ID NOs: 78-97. The peptide sequence can be one of SEQ ID NOs: 78-97, or 78-91, or 92-97. A cell-targeting compound can include a conformationally-constrained kinked peptide linked to a branched linker with one branch arm linked to a specific targeting moiety and one branch ann linked to a general targeting moiety. The specific targeting moiety can be an antibody. The general targeting moiety can be a lipid or cholesterol derivative.
-
-
-
-
-
-
-
-
-